Brief: Tenaya Therapeutics Q2 Net Income USD -23.283 Million Vs. IBES Estimate USD -25.9 Million

Tenaya Therapeutics

06/08/2025 21:30

Overview

Tenaya Therapeutics Q2 net loss of $23.3 mln narrows

Co completes enrollment in key gene therapy trials, enabling dose expansion

Cash reserves expected to support operations into second half of 2026

Outlook

Tenaya anticipates TN-201 and TN-401 data readouts in Q4 2025

Company expects cash runway into second half of 2026

Result Drivers

TRIAL ENROLLMENT - Completion of enrollment in TN-201 and TN-401 trials enables dose expansion, per CEO Faraz Ali

SAFETY APPROVAL - Positive DSMB safety review allows dose escalation for TN-201 and TN-401 trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
Beat
-$23.28 mln
-$25.90 mln (5 Analysts)
Q2 Operating Income
Beat
-$24.08 mln
-$26.30 mln (4 Analysts)
Q2 Pretax Profit
Beat
-$23.28 mln
-$25.90 mln (5 Analysts)
Q2 Basic EPS
-$0.14
Q2 Operating Expenses
$24.08 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $5.00, about 86.1% above its August 5 closing price of $0.70

Press Release: ID:nGNX8sTDLv

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)